```html

Nephrocalcinosis – A Complete Patient‑Friendly Guide

Overview

Nephrocalcinosis is the deposition of calcium salts (usually calcium oxalate, calcium phosphate, or a mixture of both) within the renal parenchyma— the functional tissue of the kidney. It is distinct from kidney stones, which form in the collecting system and may pass or cause blockage. Nephrocalcinosis can be diffuse (affecting large portions of the kidney) or focal (limited to a small area).

Although it can occur at any age, the condition is most commonly identified in:

• Children with inherited metabolic disorders (e.g., primary hyperoxaluria, distal renal tubular acidosis).
• Adults with chronic hypercalcemia, hyperparathyroidism, sarcoidosis, or prolonged use of certain medications (e.g., vitamin D excess, loop diuretics).

Exact prevalence is difficult to determine because many cases are asymptomatic and discovered incidentally on imaging. Population‑based studies suggest a prevalence of 0.5–1.5 % in adults undergoing abdominal CT for unrelated reasons, with higher rates (up to 10 %) in patients with known risk factors such as hyperparathyroidism or renal tubular acidosis.<sup>[1] Mayo Clinic</sup>

Symptoms

Many individuals have no symptoms, especially in early disease. When symptoms arise, they usually reflect underlying kidney dysfunction or associated metabolic conditions. Below is a comprehensive list:

General renal‑related symptoms

• Flank or back pain – dull, constant ache often bilateral.
• Hematuria – visible (gross) or microscopic blood in the urine.
• Polyuria – increased urine volume, sometimes accompanied by nocturia.
• Polydipsia – excessive thirst due to dilute urine.
• Recurrent urinary tract infections (UTIs) – may be a clue in children.

Signs of impaired kidney function

• Fatigue or generalized weakness.
• Swelling (edema) of ankles, feet, or face.
• Elevated blood pressure (hypertension).
• Decreased appetite, nausea, or unexplained weight loss.

Symptoms linked to specific causes

• Kidney stones – colicky pain, hematuria, or obstruction.
• Metabolic acidosis (from renal tubular acidosis) – rapid breathing, growth retardation in children.
• Hyperparathyroidism – bone pain, fractures, constipation.

Causes and Risk Factors

Nephrocalcinosis results from an imbalance between calcium (or oxalate) concentration in the renal tubules and the kidney’s ability to dissolve or clear these crystals. The main categories are:

Metabolic and Genetic Disorders

• Primary hyperoxaluria (type 1, 2, 3) – enzyme deficiencies lead to massive oxalate overproduction.
• Distal renal tubular acidosis (dRTA) – impaired acid secretion creates an alkaline tubular environment favoring calcium phosphate precipitation.
• Autosomal dominant/recessive polycystic kidney disease (ADPKD/ARPKD) – cystic changes can trap calcium.
• Familial hypomagnesemia – low magnesium promotes oxalate crystal formation.

Systemic Diseases

• Hyperparathyroidism (primary or secondary) – excess PTH raises serum calcium.
• Sarcoidosis – granulomatous production of 1,25‑(OH)2 vitamin D increases calcium absorption.
• Medullary sponge kidney – congenital dilation of collecting ducts predisposes to calcium deposition.
• Chronic kidney disease (CKD) – disturbances in calcium/phosphate metabolism.

Medications & Dietary Factors

• High‑dose vitamin D or calcium supplements.
• Loop diuretics (e.g., furosemide) that increase calcium excretion.
• Topiramate or carbonic anhydrase inhibitors that cause alkaline urine.
• Excessive oxalate‑rich foods (spinach, rhubarb, nuts) in susceptible individuals.

Other Risk Factors

• Family history of nephrocalcinosis or stone disease.
• Female sex (some studies report a slight female predominance in pediatric cases).
>
• Living in regions with hard water (high calcium content) – modestly increases risk.

Diagnosis

Because early disease can be silent, a high index of suspicion and targeted testing are essential.

Imaging Studies

• Non‑contrast CT scan – gold standard; detects tiny calcium deposits (radiodensity >100 HU) even when ultrasound is normal.
• Renal ultrasound – useful in children and pregnant patients; shows echogenic medullary pyramids, “snowstorm” appearance.
• Plain abdominal X‑ray (KUB) – may reveal diffuse renal calcifications but less sensitive.

Laboratory Evaluation

• Serum chemistries – calcium, phosphate, magnesium, bicarbonate, creatinine, and PTH.
• Urine studies (24‑hour collection) – calcium, oxalate, citrate, uric acid, pH, and volume.
• Genetic testing – indicated when primary hyperoxaluria or hereditary RTA is suspected.
• Blood gas analysis – assesses metabolic acidosis in RTA.

Additional Tests (as needed)

• Kidney biopsy – rarely required; used when atypical patterns are seen.
• Bone density scan – if hyperparathyroidism is suspected.
• Serologic tests for sarcoidosis (ACE level, chest imaging).

Treatment Options

Treatment is individualized, aiming to (1) halt further calcification, (2) dissolve existing deposits when possible, and (3) manage underlying systemic disease.

Medical Management

• Hydration – encourage ≥2–3 L of fluid per day (or as tolerated) to dilute urine and reduce supersaturation.
• Dietary modifications – low‑oxalate diet, moderate calcium (not restricted unless hypercalcemia), reduced sodium, and adequate potassium.
• Thiazide diuretics – decrease urinary calcium excretion; useful in hypercalciuric patients without contraindications.
• Potassium citrate – raises urinary citrate (a natural inhibitor of stone formation) and alkalinizes urine in certain RTA types.
• Pyridoxine (vitamin B6) – high‑dose therapy (5–20 mg/kg/day) can reduce oxalate production in primary hyperoxaluria type 1.
• Bisphosphonates – occasionally used in hyperparathyroidism‑related calcium excess.
• Specific disease‑directed therapy:
  • Parathyroidectomy for primary hyperparathyroidism.
  • Corticosteroids or immunosuppressants for sarcoidosis.
  • Alkali therapy (sodium bicarbonate) for distal RTA.

Procedural Interventions

• Percutaneous nephrolithotomy (PCNL) or ureteroscopy – indicated when large calcium deposits form obstructive stones.
• Dialysis/Transplant – in end‑stage renal disease (ESRD) caused by severe, unremitting nephrocalcinosis.

Emerging Therapies

• Liver‑kidney transplant – curative for primary hyperoxaluria type 1, replacing the deficient enzyme (AGT) in the liver.
• RNA interference (RNAi) agents – e.g., lumasiran approved by FDA (2020) to reduce oxalate production in hyperoxaluria.

Living with Nephrocalcinosis

Effective self‑management reduces progression and improves quality of life.

Hydration Strategies

• Carry a reusable water bottle; set reminders to drink every 30 minutes.
• Flavor water with citrus (lemon/lime) to increase citrate intake.
• Avoid sugary drinks, excessive caffeine, and alcohol, which can promote dehydration.

Dietary Tips

• Limit high‑oxalate foods: spinach, beets, nuts, chocolate, tea.
• Consume calcium‑rich foods (dairy, fortified plant milks) with meals to bind oxalate in the gut.
• Keep sodium intake <2,300 mg/day; high sodium raises calcium excretion.
• Maintain adequate dietary potassium (fruits, vegetables) unless hyperkalemia is an issue.

Medication Adherence

• Use a pill organizer or app reminders.
• Discuss any side effects promptly; dose adjustments may be needed.

Regular Monitoring

• Serum calcium, phosphate, and creatinine every 3–6 months (or as directed).
• 24‑hour urine collection annually to track calcium/oxalate excretion.
• Imaging (ultrasound or low‑dose CT) every 1–2 years to assess calcification burden.

Lifestyle Considerations

• Engage in moderate‑intensity exercise (e.g., brisk walking) 150 min/week to support cardiovascular health and blood pressure control.
• Avoid nephrotoxic agents such as non‑steroidal anti‑inflammatory drugs (NSAIDs) unless prescribed.
• Vaccinate against influenza and pneumococcus—CKD patients have higher infection risk.

Prevention

While not all cases are preventable (especially genetic forms), many risk factors are modifiable.

• Maintain adequate hydration throughout life; aim for urine output >2 L/day.
• Balanced diet with normal calcium, low sodium, and controlled oxalate intake.
• Regular medical follow‑up for known metabolic disorders, hyperparathyroidism, or sarcoidosis.
• Medication review—discuss with your provider if you need long‑term high‑dose vitamin D or certain diuretics.
• Genetic counseling for families with known hereditary causes.

Complications

If left untreated, nephrocalcinosis can lead to serious health issues:

• Chronic kidney disease (CKD) progression – calcifications disrupt normal nephron architecture.
• End‑stage renal disease (ESRD) – may require dialysis or transplant.
• Recurrent kidney stones – increase risk of obstruction, infection, and pain.
• Hypertension – secondary to impaired renal sodium handling.
• Bone disease – especially in hyperparathyroidism, leading to fractures.
• Growth retardation in children with severe metabolic acidosis.

When to Seek Emergency Care

---

References

• 1. Mayo Clinic. “Nephrocalcinosis.” Accessed May 2024. https://www.mayoclinic.org
• 2. National Institutes of Health – National Kidney Foundation. “Kidney Stones and Nephrocalcinosis.” Updated 2023.
• 3. Cleveland Clinic. “Primary Hyperoxaluria.” 2023.
• 4. WHO. “Guidelines for the Management of Chronic Kidney Disease.” 2022.
• 5. FDA. “Lumasiran (OXLUMO) Prescribing Information.” 2020.

```